| 000 | 01868 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516194929.0 | ||
| 264 | 0 | _c20140502 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2013.53.6029 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHwang, Clara | |
| 245 | 0 | 0 |
_aThe Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMar 2014 |
||
| 300 |
_a729-34 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aBiopsy |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xblood supply |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFatal Outcome |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xblood supply |
| 650 | 0 | 4 |
_aLiver Neoplasms _xsecondary |
| 650 | 0 | 4 |
_aLung Neoplasms _xblood supply |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aNeoplasm Grading |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPrecision Medicine |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aTumor Burden |
| 700 | 1 | _aHeath, Elisabeth I | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 32 _gno. 8 _gp. 729-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2013.53.6029 _zAvailable from publisher's website |
| 999 |
_c23534729 _d23534729 |
||